StockData
Aardvark Therapeutics, Inc. logo

Aardvark Therapeutics, Inc. (AARD) stock

AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.92−0.08 (-7.74%)

Close on Nov 20, 2026Market cap $20.19MP/E –Yield –

Aardvark Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Aardvark Therapeutics

Aardvark Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Aardvark Therapeutics figures

See a number that looks wrong?